Maximal Androgen Blockade in Prostatic Cancer

REFERENCES

• Møller Jensen O, Estève J, Moller H, Renard H. Cancer in the European Community and its Member States. Eur J Cancer 1990; 26: 1167–1256.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies in prostatic cancer. I. The effects of castration, of estrogens and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.
   Google Scholar
• Denis L. The Medical Management of Prostate Cancer II. ESO Monograph Series. Heidelberg, Springer Verlag, 1991; 110 p.
   Google Scholar
• Denis L, Mahler C. LHRH agonist combination treatment. Motta M, Serio M (eds) Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects. Amsterdam, Medicom 1987; 85–92.
   Google Scholar
• Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011–1021.
   PubMedGoogle Scholar
• De Voogt H. Prognostic factors. Furr BJA, Denis L (eds) Clinical Oncology: International Practice and Research. Prostatic Cancer. London, Baillière Tindall 1988; 521–52–6.
   Google Scholar
• Keuppens F, Fossa S, Nowè P, Denis L. Secondary orchidectomy in patients with prostatic cancer in relapse. Denis L, Murphy G, Prout GR Jr, Schröder F (eds) Controlled Clinical Trials in Urologie Oncology. New York. Raven Press 1984; 207–209.
   Google Scholar
• Huggins C, Scott WW. Bilateral adrenalectomy in prostatic cancer. Ann Surgery 1945; 122: 1031–1041.
   Web of Science ®Google Scholar
• Mahler C. Second-line endocrine treatment in advanced prostate cancer. Denis L (ed) The Medical Management of Prostate Cancer II. ESO Monograph Series. Heidelberg, Springer Verlag (in press)
   Google Scholar
• Bracci U. Antiandrogens in the treatment of prostatic cancer. Eur Urol 1979; 5: 303–306.
   PubMed Web of Science ®Google Scholar
• Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989; 33(suppl): 45–52.
   PubMedGoogle Scholar
• Labrie F, Dupont A, Bèlanger A. A complete androgen blockade for the treatment of prostate cancer. de Vita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. Philadelphia, JB Lippincott 1985; 193–200.
   Google Scholar
• Denis L, Smith PH, Carneiro de Moura JL, Newling DWW, Bono A, Keuppens F, Robinson M, Mahler C, Sylvester R, De Pauw M, Vermeulen K, Ongena P, Members of the EORTC GU Group. Orchidectomy vs Zoladex plus Flutamide in patients with metastatic prostate cancer. Eur Urol 1990; 18: 34–40.
   PubMedGoogle Scholar
• Iversen P, Danish Prostatic Cancer Group (DAPROCA). Zoladex plus Flutamide vs orchidectomy for advanced prostatic cancer. Eur Urol 1990; 18: 41–44.
   PubMedGoogle Scholar
• Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benso R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of Leuprolide with and without Flutamide in prostatic carcinoma. New Engl J Med 1988; 321: 419–429.
   Google Scholar
• Bèland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Vernier PM, Tewari HD. A controlled trial of castration with and without Nilutamide in metastatic prostatic carcinoma. Cancer 1990; 66 (suppl): 1074–1079.
   PubMedGoogle Scholar
• Baulieu EE. Studies on the secretion and interconversion of the androgens. Recent Progress in Hormone Research 1963; 19: 306.
   Google Scholar
• Harper ME, Pike A, Peeling WB, Griffiths K. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrin 1974; 60: 117–125.
   PubMed Web of Science ®Google Scholar
• Labrie F, Bèlanger A, Veilleux R, Lacoste D, Labrie C, Marchetti B, Poulin R, Dupont A, Cusan L, Luthy I. Rationale for maximal androgen withdrawal in the therapy of prostate cancer. Furr BJA, Denis L (eds) Clinical Oncology: International Practice and Research. Prostatic Cancer. London. Baillière Tindall 1988; 597–619.
   Google Scholar
• Oesterling JE, Epstein JI, Walsh PC. The unability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J Urol 1986; 136: 1030–1034.
   PubMed Web of Science ®Google Scholar
• Van Steenbrugge GJ, van Dongen JJW, Reuvers PJ, de Jong FH, Schröder FH. Transplantable human prostatic carcinoma (PC—82) in athymic nude mice. I. Hormone dependence and the concentration of androgens in plasma and tumor tissue. Prostate 1987; 11: 195–210.
   PubMedGoogle Scholar
• Isaacs JT, Wake N, Coffey DS, Sandberg AA. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R—3327 rat prostatic adenocarcinoma system. Cancer Research 1982; 42: 2353–2361.
   PubMed Web of Science ®Google Scholar
• Schröder FH, Van Steenbrugge GJ. Rationale against total androgen withdrawal. Furr BJA, Denis L (eds) Clinical Oncology: International Practice and Research. Prostatic Cancer. London, Baillière Tindall 1988; 621–633.
   Google Scholar
• Murphy GP. Proceedings of the Workshop on Combined Castration and Androgen Blockade Therapy in Prostate Cancer: Results and Future Directions. Cancer 1990; 66 (suppl): 1007–1089.
   PubMedGoogle Scholar
• Bèland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD. Total androgen ablation: Canadian experience. Urol Clin NA 1991; 18: 72–82.
   Google Scholar
• Iversen P, Suciu S, Sylvester R, Christensen I, Denis L. Zoladex and Flutamide versus orchiectomy in the treatment of advanced prostatic cancer: A combined analysis of two European studies. EORTC 30853 and DAPROCA 086. Cancer 1990; 66 (suppl): 1067–1073.
   PubMedGoogle Scholar
• Denis L, Mettlin C. Conclusions from the Workshop. Cancer 1990; 66 (suppl): 1086–1089.
   PubMedGoogle Scholar
• Dalesio O. Complete androgen blockade in prostate cancer: Organizing an overview. Cancer 1990; 66 (suppl): 1080–1082.
   PubMedGoogle Scholar